1-(3,4-二氯苯基)-3-吡啶-3-基脲 | 13142-48-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3,4-二氯苯基)-3-吡啶-3-基脲
• 英文名称: 1-(3,4-dichloro-phenyl)-3-pyridin-3-yl-urea
• 英文别名: 1-(3,4-Dichlorophenyl)-3-pyridin-3-ylurea
• CAS: 13142-48-8
• 化学式: C₁₂H₉Cl₂N₃O
• 分子量: 282.129
• InChiKey: XJNYDCGOJJLPLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  3-氨基吡啶 、 3,4-二氯苯异氰酸酯 以 二氯甲烷 为溶剂， 生成 1-(3,4-二氯苯基)-3-吡啶-3-基脲
  参考文献：
  名称：

  Antischistosomal activity of N,N′-arylurea analogs against Schistosoma japonicum

  摘要：

  Although the antischistosomal activities of N,N'-arylurea analogs were reported, systematic structure-activity relationships have not been conducted. In this Letter, we reported the design, synthesis and evaluation of 45 N,N'-arylurea analogs. Among these prepared compounds, 13 compounds were urea linker modified and 32 were N,N'-arylurea derivatives. The activity evaluation revealed 12 analogs exhibited IC50 values lower than 22.6 mu M, and 7 of them had IC50 less than 10 mu M against the juvenile Schistosoma japonicum in vitro. Their worm killing potency was even higher against adult worm. Unfortunately, low to moderate worm burden reduction of 0-33.4% was recorded after administration of a single oral dose of 200 mg/kg or 400 mg/kg to mice harboring S. japonicum. (C) 2016 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2016.01.075

文献信息

• Model studies on a synthetically facile series of N-substituted phenyl-N′-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT2C/2B receptor antagonists
  作者：Steven M. Bromidge、Steven Dabbs、David T. Davies、Susannah Davies、D.Malcolm Duckworth、Ian T. Forbes、Angela Gadre、Peter Ham、Graham E. Jones、Frank D. King、Damian V. Saunders、Kevin M. Thewlis、Deepa Vyas、Thomas P. Blackburn、Vicky Holland、Guy A. Kennett、Graham J. Riley、Martyn D. Wood

  DOI：10.1016/s0968-0896(99)00228-x

  日期：1999.12

  antagonists have been prepared by rapid parallel synthesis. These N-substituted phenyl-N'-pyridin-3-yl ureas were found to have a range of 5-HT2C receptor affinities and selectivities over the closely related 5-HT2A receptor. Extrapolation of simple SAR, derived from this set of compounds, to the more active but synthetically more complex 1-(3-pyridylcarbamoyl)indoline series allowed us to target optimal

  已经通过快速平行合成制备了一系列的5-HT 2C拮抗剂模型。发现这些N-取代的苯基-N'-吡啶-3-基脲比密切相关的5-HT2A受体具有一系列的5-HT2C受体亲和力和选择性。从这组化合物中衍生出的简单SAR外推至活性更高但合成上更复杂的1-（3-吡啶基氨基甲酰基）二氢吲哚系列，使我们能够靶向最佳取代模式并鉴定有效和选择性的5-HT（2C / 2B）拮抗剂。
• COMPOUNDS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION
  申请人：Universidad Autónoma de Madrid

  公开号：EP3275863A1

  公开（公告）日：2018-01-31

  The present invention relates to the medicinal use of small organic compounds, in particular amide and urea derivatives, for the treatment of congenital disorders of glycosylation, and in particular PMM2 congenital disorder of glycosylation.

  本发明涉及小型有机化合物，特别是酰胺和脲衍生物在治疗先天性糖基化紊乱，尤其是PMM2先天性糖基化紊乱方面的药用用途。
• USE OF PHENYL HETEROARYL UREAS AS 5HT 2C? RECEPTOR ANTAGONISTS AND UREA COMPOUNDS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0682656A1

  公开（公告）日：1995-11-22
• [EN] USE OF PHENYL HETEROARYL UREAS AS 5HT2C RECEPTOR ANTAGONISTS AND UREA COMPOUNDS<br/>[FR] UTILISATION D'UREES D'HETEROARYLE DE PHENYLE COMME ANTAGONISTES DE RECEPTEUR DE 5HT2C ET COMPOSES D'UREE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1994018170A1

  公开（公告）日：1994-08-18

  (EN) The use of a compound of formula (I) or a salt thereof, wherein P represents a quinoline or isoquinoline residue or a 5- or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur; R1 is hydrogen, C1-6 alkyl, halogen, NR5R6 or OR7 where R5, R6 and R7 are independently hydrogen or C1-6 alkyl; R2 and R3 are independently hydrogen or C1-6 alkyl; R4 is hydrogen, C1-6 alkyl, CF3, nitro, cyano, acyl, halogen, NR5R6, OR7 or CO2R7 where R5, R6 and R7 are independently hydrogen or C1-6 alkyl as defined for R1; and n is 1, 2 or 3, in the manufacture of a medicament for the treatment or prophylaxis of CNS disordres.(FR) Utilisation d'un composé de la formule (1) ou d'un sel de ce composé, formule dans laquelle P représente un reste de quinoline ou d'isoquinoline ou un noyau hétérocyclique aromatique à 5 ou 6 éléments contenant jusqu'à trois hétéroatomes choisis entre azote, oxygène et soufre; R1 représente hydrogène, alkyle C1-6, halogène, NR5R6 ou OR7, R5, R6 et R7 représentant indépendamment hydrogène ou alkyle C1-6; R4 représente hydrogène, alkyle C1-6, CF3, nitro, cyano, acyle, halogène, NR5R6, OR7 ou CO2R7, R5, R6 et R7 représentant indépendamment hydrogène ou alkyle C1-6 tels que définis pour R1; et n vaut 1, 2 ou 3. Ce composé ou son sel peuvent être utilisés pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de troubles du système nerveux central.
• [EN] COMPOUNDS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES CONGÉNITAUX DE LA GLYCOSYLATION
  申请人：UNIV AUTÓNOMA DE MADRID

  公开号：WO2018019987A1

  公开（公告）日：2018-02-01

  The present invention relates to the medicinal use of small organic compounds, in particular amide and urea derivatives, for the treatment of congenital disorders of glycosylation, and in particular PMM2 congenital disorder of glycosylation.